This is the key line in today's press release. I think it provides a major hint about how they feel the Mayo validation study is going and that is why shares are breaking out pre-market:
"RPC has been invited to present at various scientific and medical conferences, including the upcoming European Multidisciplinary Conference in Thoracic Oncology (EMCTO) international conference, 24-26 February 2011, where the Company will present an abstract under the title of "The Validation of Fibrin and Fibrinogen Degradation Products Assay for Early Detection of Lung Cancer."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.